Hattori, Nobutaka http://orcid.org/0000-0002-2034-2556
Takeda, Atsushi
Takeda, Shinichi
Nishimura, Akira
Kitagawa, Tadayuki
Mochizuki, Hideki
Nagai, Masahiro
Takahashi, Ryosuke
Funding for this research was provided by:
Takeda Pharmaceutical Company (Not applicable)
Article History
Received: 23 August 2018
Accepted: 12 December 2018
First Online: 28 January 2019
Compliance with ethical standards
:
: Nobutaka Hattori has served on advisory boards for Hisamitsu Pharmaceutical Co Inc., Sumitomo Dainippon Pharma Co. Ltd, Ono Pharmaceutical Co. Ltd, Otsuka Pharmaceutical Co. Ltd, Novartis Pharma K.K., and Takeda Pharmaceutical Co. Ltd; has performed corporate-sponsored research for Takeda Pharmaceutical Co. Ltd; has received honoraria from GlaxoSmithKline K.K., Nippon Boehringer Ingelheim Co. Ltd, FP Pharmaceutical Corporation, Sumitomo Dainippon Pharma Co. Ltd, Eisai Co. Ltd, Kissei Pharmaceutical Company, Nihon Medi-Physics Co. Ltd, Kyowa Hakko Kirin Co. Ltd, Novartis Pharma K.K, Biogen Japan Ltd, Acorda Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd, Janssen Pharmaceutical K.K, Medtronic Japan Co. Ltd, and Astellas Pharma Inc.; has received donations from Astellas Pharma Inc., Eisai Co. Ltd, MSD K.K., Daiichi Sankyo Co. Ltd, Novartis Pharma K.K., Takeda Pharmaceutical Co. Ltd, Nihon Medi-Physics Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Pfizer Japan Inc., Bayer Yakuhin Ltd, FP Pharmaceutical Corporation, Shionogi & Co. Ltd, and MSD; and has received donations for the endowed research departments of GlaxoSmithKline K.K., Nippon Boehringer Ingelheim, Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Eisai Co. Ltd, Kissei Pharmaceutical Co., Nihon Medi-Physics Co. Ltd, Kyowa Hakko Kirin Co. Ltd, Medtronic Japan Co. Ltd, Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Co., Zaiho Co. Ltd, Asahi Kasei Medical Co. Ltd, and MiZ Co. Ltd. Atsushi Takeda has served on advisory boards for AbbVie Inc., Kyowa Hakko Kirin Co. Ltd, and Takeda Pharmaceutical Co. Ltd; has performed corporate-sponsored research for Hisamitsu Pharma Co. Inc., Meiji-Seika Pharma Co. Ltd, and Pfizer Japan Inc.; and has received honoraria from AbbVie Inc., Sumitomo Dainippon Pharma Co. Ltd, and Kyowa Hakko Kirin Co. Ltd. Shinichi Takeda, Tadayuki Kitagawa, and Akira Nishimura are employees of Takeda Pharmaceutical Co. Ltd. Hideki Mochizuki has served on advisory boards for Hisamitsu Pharmaceutical Co., Inc., and Takeda Pharmaceutical Co. Ltd; has received honoraria from FP Pharmaceutical Corporation, Sumitomo Dainippon Pharma Co. Ltd, Nihon Medi-Physics Co. Ltd, Kyowa Hakko Kirin Co. Ltd, Novartis Pharma K.K., and Otsuka Pharmaceutical Co. Ltd; and has received donations from Nihon Medi-Physics Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, and Kyowa Hakko Kirin Co. Ltd. Masahiro Nagai has served on an advisory board for Takeda Pharmaceutical Co. Ltd; and has received honoraria from Novartis Pharma K.K. Ryosuke Takahashi is an employee of the Japan Agency for Medical Research and Development; has served on advisory boards for Kan Institute Co. Ltd and Sumitomo Dainippon Pharma Co. Ltd; has performed corporate-sponsored research for Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd, Nippon Boehringer Ingelheim Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Kyowa Hakko Kirin Co. Ltd, Nihon Medi-Physics Co. Ltd, Mitsubishi Tanabe Pharma Co. and Konica Minolta Inc.; and has received honoraria from Sumitomo Dainippon Pharma Co Ltd. and FP Pharmaceutical Co.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.